Source: Annual Congress 2002 - Asthma - Therapy and management -2
Disease area: Airway diseases

Abstract

Very little is known about the efficacy of inhaled corticosteroids for the early management of acute exacerbations of asthma at home or in the emergency room. This randomized, double-blind, placebo-controlled study was therefore conducted to evaluate the efficacy of high dose inhaled fluticasone propionate with frequent beta-2-agonist therapy in patients of acute moderate exacerbations of asthma.
Seventy patients between 15 and 40 years of age with an acute moderate exacerbations of asthma were put on aerosolized 500 mcg of fluticasone at half hourly intervals for three doses with metered dose inhaler and spacer. All patients received humidified oxygen and nebulized salbutamol (0.15 mg/kg in 3 ml saline) prior to fluticasone administration. The control group received placebo instead of inhaled fluticasone. Patients who had received corticosteroids in the preceding 72 h were excluded from this study. If there was an inadequate response or no response to treatment at the end of 2 hour, oxygen and salbutamol therapy were continued and given one dose of intravenous hydrocortisone and was started on an aminophylline infusion. Both fluticasone and control group showed a significant improvement in respiratory status at the end of 2 h. However, patients in the fluticasone group showed greater improvement in PEFR (p<0.05) and significantly lower proportion of patients required oxygen therapy for more than 2 h (p<0.05). The length of stay was significantly shorter in the fluticasone group than in the placebo group (p<0.01).
Aerosolized fluticasone therapy with MDI and spacer together with salbutamol in the treatment of acute exacerbations of asthma helped in early recovery and decreased hospital stay.

Rating:

Share or cite this content

Citations should be made in the following way:
S. K. Agarwal, D. S. Gupta (Varanasi, India). Aerosolized fluticasone propionate therapy in acute moderate exacerbations of asthma. Eur Respir J 2002; 20: Suppl. 38, 397

Member's Comments

No comment yet.

Related content which might interest you: Effect of discontinuation of inhaled fluticasone propionate on exacerbations in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 183s Year: 2001 Aerosolized budesonide therapy in acute moderate exacerbations of Indian asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 343s Year: 2004 Utility of aerosolized budesonide therapy in acute moderate exacerbations of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 283s Year: 2003 Utility of high dose inhaled fluticasone therapy for the early management of acute exacerbations of asthma Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001 Inhalation of fluticasone propionate spray compared with theophilline as primary treatment for chronic mild to moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 500s Year: 2006 The role of nebulised budesonide in the treatment of acute exacerbations of COPD Source: Eur Respir J 2007; 30: 399-400 Year: 2007 Comparison of oral prednisolone and nebulized budesonide in the treatment of acute exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 214s Year: 2001 Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004 Efficacy of high-dose inhaled fluticasone propionate in Indian patients having moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002 Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD Source: Eur Respir J 2004; 24: Suppl. 48, 513s Year: 2004 Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Clinical efficacy of nebulised budesonide in acute exacerbation of COPD Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 Efficacy of inhaled ciclesonide compared with oral prednisolone in the treatment of asthma exacerbations Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006 Sustained reduction of bronchial hyperresponsiveness with inhaled fluticasone propionate in mild asthma within three days Source: Eur Respir J 2002; 20: Suppl. 38, 197s Year: 2002 Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004 Nebulized beclomethasone dipropionate is as effective and as well tolerated than nebulized budesonide to prevent asthma exacerbations in infants Source: Eur Respir J 2001; 18: Suppl. 33, 122s Year: 2001 The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007 Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006